European project PANBioRA
Personalised and Generalised Integrated Biomaterial Risk Assessment
PANBioRA aims at providing a comprehensive solution for the time- and cost-effective risk assessment of:
- new biomaterials under health or disease states or
- a given biomaterial for each patient in a personalised manner
It will standardize the evaluation of biomaterials and open the venue for pre-implantation, personalized diagnostics for biomaterial-based applications. This measure will allow for the selection of the best suitable material, minimizing side effects and improving health outcomes.
The 17 PANBioRA partners will provide a modular platform to assess risks at different aspects and length scales. These comprise antibody response, cytotoxicity/genotoxicity, systemic and local effects at tissue and connected tissues (organ-on-a-chip). Moreover, physicochemical and biomechanical characterisation as well as predictive modelling at systems level will complement the system. This will be achieved by connecting testing modules in a structure supported by web-based modelling and risk radar tools together with a biomechanical testing system.
The project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 760921 and is conducted under the topic titled "Development of a reliable methodology for better risk management of engineered biomaterials in Advanced Therapy Medicinal Products and/or Medical Devices". The budget is around 7,9 Mio. Euro.
Project Duration: 01/2018-12/2021
Participating Countries: Albania, Belgium, Czech Republic, Estonia, Finland, France, Germany, Ireland, Serbia, Spain, UK